Hunter Cancer Research Alliance
As a multidisciplinary and multi-institutional alliance, the Hunter Cancer Research Alliance (HCRA) functions to provide capacity building, funding and strategic support to cancer research across the translational research continuum – from basic research through clinical trials to behavioural, implementation and health services research.
With the support of our partnering institutions, executive leaders and a membership that consists of 250+ cancer-focused researchers, we are working to promote the excellence of cancer research in the Hunter and ultimately improve cancer patient outcomes in our region and beyond.
HCRA Director, Professor Stephen Ackland, explains the work of HCRA in the video below:
Health Education Research Advance Access
The association between cannabis use and motivation and intentions to quit tobacco within a sample of Australian socioeconomically disadvantaged smokers
Laura Twyman1, Billie Bonevski, Christine Paul, Frances J. Kay-Lambkin, Jamie Bryant, C. Oldmeadow, K. Palazzi4 and A. Guillaumier
This study aimed to (i) describe concurrent and simultaneous tobacco and cannabis use and (ii) investigate the association between cannabis use and motivation and intentions to quit tobacco in a sample of socioeconomically disadvantaged smokers. A cross-sectional survey was conducted in 2013 and 2014 with current tobacco smokers
receiving aid fromtwo community service organizations in New South Wales, Australia. At least weekly cannabis use for the month prior to survey, motivation to quit tobacco and intentions to quit tobacco were measured in 369 participants (77% consent rate). Regressions were carried out to investigate associations between weekly cannabis use and motivation and intentions to quit tobacco.
Concurrent tobacco and cannabis use was reported by 19%(n¼71) of the sample and of these users, 100% reported simultaneous use. Although regular cannabis use was significantly associated with lower motivation to quit tobacco, it was not significantly associated with intentions to quit tobacco in the next 30 days. Concurrent
cannabis use is common in disadvantaged smokers and may play a role in decreasedmotivation to quit tobacco; however, it does not appear to be associated with intentions to quit in a sample of disadvantaged smokers.
May: Twyman, L. et al (2016) Electronic Cigarettes: Awareness, Recent Use, and Attitudes within a sample of Socioeconomically disadvantaged Australian Smokers. Nicotine & Tocacco Research 18(5):670-677
July: Smith, A.M. et al (2016) Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, Advanced Publications 2016
September: Goulooze. S.C. et al (2016) Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. Cancer Chemother Pharmacol (2016) 78:209-2016.
November: Vahid Heravi Shargh et al (2016) Albumin Hybrid Nanoparticles Loaded with Tyrosine Kinase A Inhibitor GNF-5837 for Targeted Inhibition of Breast Cancer Cell Growth and Invasion. International Journal of Pharmaceutics.